drugset / Trial / NCT06835400
Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).
Timeline
- Start
- 2025-09
- Primary completion
- 2028-04
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM30181AK | Unknown | — | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Oral |
| Subject | Paclitaxel | Small molecule | 165 mg/m2 | Oral |
| Subject | Paclitaxel | Small molecule | 205 mg/m2 | Oral |